CAI Form 4: 104.8M Shares Converted, Founder Holds 121M Post-IPO

Q: How many Caris Life Sciences (CAI) shares does David D. Halbert own after the reported transactions?

He beneficially owns about 121.0 million common shares (鈮�2.4 million direct, the rest indirect through affiliated entities).

Q: What triggered the preferred-stock conversion disclosed in the Caris Life Sciences Form 4?

Each Series A and Series B share automatically converted into common stock at IPO closing on 20 June 2025 at a 0.25:1 ratio.

Q: Were any shares sold by the insider in this filing?

No. All transactions were awards or automatic conversions ; no dispositions or open-market sales occurred.

Q: Does the Form 4 indicate additional dilution for CAI shareholders?

Yes. The conversion adds ~104.8 million new common shares , expanding the share base ahead of public trading.

[Form 4] Caris Life Sciences, Inc. Insider Trading Activity

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Form 4 highlights for Caris Life Sciences, Inc. (CAI): Founder, Chairman and CEO David D. Halbert 鈥� together with investment vehicle Caris Halbert, L.P. 鈥� reported multiple equity transactions surrounding the company鈥檚 initial public offering (IPO) and a 1-for-4 reverse stock split effected 1 June 2025.

Key common-stock activity

03 Mar 2025: Award of 360,750 restricted stock units (RSUs) at no cost; direct holdings rose to 2,023,250 shares.
18 Jun 2025: Award of 413,839 RSUs; direct holdings rose to 2,437,089 shares.
20 Jun 2025: Automatic conversion of preferred shares into 104,761,535 common shares (Code C) upon IPO closing; holdings recorded as indirect.

Derivative securities

Series A Preferred (389,416,484 shares) and Series B Preferred (29,629,630 shares) converted at $0 exercise price for 97,354,127 and 7,407,408 common shares, respectively. Post-conversion, no preferred remains outstanding for the filer.

Post-transaction ownership

Total beneficial ownership: 鈮�121.0 million common shares (2.44 million direct; 118.6 million indirect across Caris Halbert L.P., ADAPT I Ltd., Carisome I L.P., and other affiliates).
Halbert remains a Director, 10% owner, and CEO; retains voting control via affiliated entities.

Implications for investors: The conversion collapses the preferred layer, simplifying the capital structure ahead of public trading and clarifying the insider鈥檚 sizeable stake. RSU grants strengthen incentive alignment but add marginal dilution. Concentrated insider ownership (>10%) may influence governance and float dynamics post-IPO.

Aspectos destacados del Formulario 4 para Caris Life Sciences, Inc. (CAI): El fundador, presidente y CEO David D. Halbert 鈥� junto con el veh铆culo de inversi贸n Caris Halbert, L.P. 鈥� report贸 m煤ltiples transacciones de acciones relacionadas con la oferta p煤blica inicial (IPO) de la compa帽铆a y una divisi贸n inversa de acciones 1 a 4 realizada el 1 de junio de 2025.

Actividad clave en acciones ordinarias

03 de marzo de 2025: Otorgamiento de 360,750 unidades restringidas de acciones (RSU) sin costo; las participaciones directas aumentaron a 2,023,250 acciones.
18 de junio de 2025: Otorgamiento de 413,839 RSU; las participaciones directas aumentaron a 2,437,089 acciones.
20 de junio de 2025: Conversi贸n autom谩tica de acciones preferentes en 104,761,535 acciones ordinarias (C贸digo C) al cierre de la IPO; las participaciones se registraron como indirectas.

Valores derivados

Las acciones preferentes Serie A (389,416,484 acciones) y Serie B (29,629,630 acciones) se convirtieron a un precio de ejercicio de $0 en 97,354,127 y 7,407,408 acciones ordinarias, respectivamente. Despu茅s de la conversi贸n, no quedan acciones preferentes en circulaci贸n para el declarante.

Propiedad posterior a la transacci贸n

Propiedad beneficiaria total: aproximadamente 121 millones de acciones ordinarias (2.44 millones directas; 118.6 millones indirectas a trav茅s de Caris Halbert L.P., ADAPT I Ltd., Carisome I L.P. y otras afiliadas).
Halbert contin煤a siendo Director, propietario del 10% y CEO; mantiene el control de voto mediante entidades afiliadas.

Implicaciones para los inversores: La conversi贸n elimina la capa de acciones preferentes, simplificando la estructura de capital antes de la negociaci贸n p煤blica y aclarando la considerable participaci贸n de los insiders. Las concesiones de RSU fortalecen la alineaci贸n de incentivos pero generan una diluci贸n marginal. La propiedad concentrada de insiders (>10%) podr铆a influir en la gobernanza y la din谩mica del float despu茅s de la IPO.

Caris Life Sciences, Inc. (CAI)鞚� Form 4 欤检殧雮挫毄: 彀诫鞛愳澊鞛� 須岇灔瓴� CEO鞚� David D. Halbert臧€ 韴瀽彀焿 Caris Halbert, L.P.鞕€ 頃粯須岇偓鞚� 旮办梾瓿店皽(IPO) 氚� 2025雲� 6鞗� 1鞚� 鞁滍枆霅� 1雽€ 4 鞐硲頃╆臣甏€霠悳鞐煬欤检嫕瓯半灅毳� 氤搓碃頄堨姷雼堧嫟.

欤检殧氤错喌欤� 頇滊彊

2025雲� 3鞗� 3鞚�: 360,750 鞝滍暅欤检嫕雼渼(RSU) 氍挫儊靾橃棳; 歆侅爲氤挫湢欤检嫕鞚€ 2,023,250欤茧 歃濌皜.
2025雲� 6鞗� 18鞚�: 413,839 RSU 靾橃棳; 歆侅爲氤挫湢欤检嫕鞚€ 2,437,089欤茧 歃濌皜.
2025雲� 6鞗� 20鞚�: IPO 膦呺 鞁� 鞖办劆欤缄皜 104,761,535 氤错喌欤茧 鞛愲彊鞝勴櫂 (旖旊摐 C); 氤挫湢攵勳潃臧勳爲氤挫湢搿� 旮半霅�.

韺岇儩歃濌秾

鞁滊Μ歃� A 鞖办劆欤�(389,416,484欤�) 氚� 鞁滊Μ歃� B 鞖办劆欤�(29,629,630欤�)臧€ 臧侁皝 頄夓偓臧€瓴� $0搿� 97,354,127欤� 氚� 7,407,408欤� 氤错喌欤茧 鞝勴櫂霅�. 鞝勴櫂頉� 鞁犼碃鞚胳棎雽€頃� 鞖办劆欤茧姅氇憪靻岆└.

瓯半灅頉� 靻岇湢甓�

齑� 鞁れ 靻岇湢甓�: 鞎� 1鞏� 2,100毵� 氤错喌欤� (歆侅爲氤挫湢 244毵� 欤�; Caris Halbert L.P., ADAPT I Ltd., Carisome I L.P. 氚� 旮绊儉瓿勳棿靷ゼ韱淀暅臧勳爲氤挫湢 1鞏� 1,860毵� 欤�).
Halbert電� 瓿勳啀頃挫劀 鞚挫偓, 10% 靻岇湢欤�, CEO搿滌劀瓿勳棿靷ゼ韱淀暣鞚橁舶甓岇潉鞙犾.

韴瀽鞛愳棎雽€頃� 鞁滌偓鞝�: 鞚措矆鞝勴櫂鞙茧 鞖办劆欤� 瓿勳傅鞚� 頃挫唽霅橃柎靸侅灔鞝� 鞛愲掣甑“臧€ 雼垳頇旊悩瓿� 雮措秬鞛愳潣靸侂嫻頃� 歆€攵勳澊氇呿檿頃挫鞀惦媹雼�. RSU 攵€鞐姅鞚胳劶韹半笇鞝曤牞鞚� 臧曧檾頃橃毵� 氙鸽頃� 頋劃須臣臧€ 鞛堨姷雼堧嫟. 10% 鞚挫儊鞚� 歆戩霅� 雮措秬鞛� 靻岇湢電� IPO 鞚错泟歆€氚瓣惮臁� 氚� 鞙犿喌欤检嫕靾橃棎鞓來枼鞚� 氙胳範靾� 鞛堨姷雼堧嫟.

Points cl茅s du formulaire 4 pour Caris Life Sciences, Inc. (CAI) : Le fondateur, pr茅sident et PDG David D. Halbert 鈥� avec le v茅hicule d鈥檌nvestissement Caris Halbert, L.P. 鈥� a d茅clar茅 plusieurs transactions en actions li茅es 脿 l鈥檌ntroduction en bourse (IPO) de la soci茅t茅 et 脿 une division invers茅e d鈥檃ctions 1 pour 4 effectu茅e le 1er juin 2025.

Activit茅 cl茅 sur les actions ordinaires

3 mars 2025 : Attribution de 360 750 unit茅s d鈥檃ctions restreintes (RSU) gratuites ; les participations directes sont pass茅es 脿 2 023 250 actions.
18 juin 2025 : Attribution de 413 839 RSU ; les participations directes sont pass茅es 脿 2 437 089 actions.
20 juin 2025 : Conversion automatique de actions privil茅gi茅es en 104 761 535 actions ordinaires (Code C) 脿 la cl么ture de l鈥橧PO ; les participations sont enregistr茅es comme indirectes.

Instruments d茅riv茅s

Les actions privil茅gi茅es de s茅rie A (389 416 484 actions) et de s茅rie B (29 629 630 actions) ont 茅t茅 converties 脿 un prix d鈥檈xercice de 0 $ en 97 354 127 et 7 407 408 actions ordinaires respectivement. Apr猫s conversion, aucune action privil茅gi茅e n鈥檈st en circulation pour le d茅clarant.

Propri茅t茅 apr猫s la transaction

Propri茅t茅 b茅n茅ficiaire totale : environ 121 millions d鈥檃ctions ordinaires (2,44 millions en direct ; 118,6 millions indirectes via Caris Halbert L.P., ADAPT I Ltd., Carisome I L.P. et autres affili茅s).
Halbert reste directeur, propri茅taire 脿 10 % et PDG ; il conserve le contr么le des votes via des entit茅s affili茅es.

Implications pour les investisseurs : La conversion supprime la couche des actions privil茅gi茅es, simplifiant la structure du capital avant la cotation publique et clarifiant la participation importante des initi茅s. Les attributions de RSU renforcent l鈥檃lignement des incitations mais entra卯nent une dilution marginale. La concentration de la propri茅t茅 des initi茅s (>10 %) pourrait influencer la gouvernance et la dynamique du flottant apr猫s l鈥橧PO.

Positive

Preferred-to-common conversion removes senior securities, simplifying capital structure ahead of the IPO.
Founder retains a sizable equity stake (~121 M shares), aligning management incentives with shareholder value.
No insider sales were reported, reducing negative signalling risk around the IPO timing.

Negative

Approx. 105 M new common shares increase share count and potential dilution for public investors.
High insider concentration >10% may constrain free float and concentrate voting power.

Insights

TL;DR: Insider converts >104 M shares & receives RSUs; cap-structure simplified, but dilution and control concentration persist.

The automatic conversion of Series A and B preferred shares adds roughly 105 million new common shares, taking David Halbert鈥檚 total beneficial stake to ~121 million. Although the conversion was pre-programmed for the IPO at a 0.25 ratio, it materially increases the public share count, a potential overhang once the lock-up expires. Positively, eliminating preferred equity streamlines the balance sheet and removes preferential rights that might have weighed on valuation. The two RSU grants (鈮�0.77 million shares) are immaterial versus total shares but reinforce management incentives. Overall impact is modestly dilutive yet expected, leaving the disclosure neutral to slightly positive from a capital-structure perspective.

TL;DR: Halbert controls ~121 M shares post-IPO, signalling strong alignment but tight float and governance influence.

With indirect ownership spread across several affiliated partnerships and trusts, Halbert preserves voting power while disclaiming beneficial ownership beyond pecuniary interest. Such concentration may reassure investors seeking founder commitment, yet it can limit board independence and minority influence. The reverse split and conversion events demonstrate careful pre-IPO housekeeping, reducing complexity. No sales were reported, so market-signal risk is low. I view the filing as governance-neutral with a watch-flag on float and related-party oversight once the stock lists.

Actividad clave en acciones ordinarias

03 de marzo de 2025: Otorgamiento de 360,750 unidades restringidas de acciones (RSU) sin costo; las participaciones directas aumentaron a 2,023,250 acciones.
18 de junio de 2025: Otorgamiento de 413,839 RSU; las participaciones directas aumentaron a 2,437,089 acciones.
20 de junio de 2025: Conversi贸n autom谩tica de acciones preferentes en 104,761,535 acciones ordinarias (C贸digo C) al cierre de la IPO; las participaciones se registraron como indirectas.

Valores derivados

Las acciones preferentes Serie A (389,416,484 acciones) y Serie B (29,629,630 acciones) se convirtieron a un precio de ejercicio de $0 en 97,354,127 y 7,407,408 acciones ordinarias, respectivamente. Despu茅s de la conversi贸n, no quedan acciones preferentes en circulaci贸n para el declarante.

Propiedad posterior a la transacci贸n

Propiedad beneficiaria total: aproximadamente 121 millones de acciones ordinarias (2.44 millones directas; 118.6 millones indirectas a trav茅s de Caris Halbert L.P., ADAPT I Ltd., Carisome I L.P. y otras afiliadas).
Halbert contin煤a siendo Director, propietario del 10% y CEO; mantiene el control de voto mediante entidades afiliadas.

欤检殧氤错喌欤� 頇滊彊

2025雲� 3鞗� 3鞚�: 360,750 鞝滍暅欤检嫕雼渼(RSU) 氍挫儊靾橃棳; 歆侅爲氤挫湢欤检嫕鞚€ 2,023,250欤茧 歃濌皜.
2025雲� 6鞗� 18鞚�: 413,839 RSU 靾橃棳; 歆侅爲氤挫湢欤检嫕鞚€ 2,437,089欤茧 歃濌皜.
2025雲� 6鞗� 20鞚�: IPO 膦呺 鞁� 鞖办劆欤缄皜 104,761,535 氤错喌欤茧 鞛愲彊鞝勴櫂 (旖旊摐 C); 氤挫湢攵勳潃臧勳爲氤挫湢搿� 旮半霅�.

韺岇儩歃濌秾

鞁滊Μ歃� A 鞖办劆欤�(389,416,484欤�) 氚� 鞁滊Μ歃� B 鞖办劆欤�(29,629,630欤�)臧€ 臧侁皝 頄夓偓臧€瓴� $0搿� 97,354,127欤� 氚� 7,407,408欤� 氤错喌欤茧 鞝勴櫂霅�. 鞝勴櫂頉� 鞁犼碃鞚胳棎雽€頃� 鞖办劆欤茧姅氇憪靻岆└.

瓯半灅頉� 靻岇湢甓�

齑� 鞁れ 靻岇湢甓�: 鞎� 1鞏� 2,100毵� 氤错喌欤� (歆侅爲氤挫湢 244毵� 欤�; Caris Halbert L.P., ADAPT I Ltd., Carisome I L.P. 氚� 旮绊儉瓿勳棿靷ゼ韱淀暅臧勳爲氤挫湢 1鞏� 1,860毵� 欤�).
Halbert電� 瓿勳啀頃挫劀 鞚挫偓, 10% 靻岇湢欤�, CEO搿滌劀瓿勳棿靷ゼ韱淀暣鞚橁舶甓岇潉鞙犾.

Activit茅 cl茅 sur les actions ordinaires

3 mars 2025 : Attribution de 360 750 unit茅s d鈥檃ctions restreintes (RSU) gratuites ; les participations directes sont pass茅es 脿 2 023 250 actions.
18 juin 2025 : Attribution de 413 839 RSU ; les participations directes sont pass茅es 脿 2 437 089 actions.
20 juin 2025 : Conversion automatique de actions privil茅gi茅es en 104 761 535 actions ordinaires (Code C) 脿 la cl么ture de l鈥橧PO ; les participations sont enregistr茅es comme indirectes.

Instruments d茅riv茅s

Les actions privil茅gi茅es de s茅rie A (389 416 484 actions) et de s茅rie B (29 629 630 actions) ont 茅t茅 converties 脿 un prix d鈥檈xercice de 0 $ en 97 354 127 et 7 407 408 actions ordinaires respectivement. Apr猫s conversion, aucune action privil茅gi茅e n鈥檈st en circulation pour le d茅clarant.

Propri茅t茅 apr猫s la transaction

Propri茅t茅 b茅n茅ficiaire totale : environ 121 millions d鈥檃ctions ordinaires (2,44 millions en direct ; 118,6 millions indirectes via Caris Halbert L.P., ADAPT I Ltd., Carisome I L.P. et autres affili茅s).
Halbert reste directeur, propri茅taire 脿 10 % et PDG ; il conserve le contr么le des votes via des entit茅s affili茅es.

06/23/2025 - 06:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HALBERT DAVID D

(Last)

(First)

(Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING

75039

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/25/2025		A		360,750⁽¹⁾	A	$0	2,023,250	D
Common Stock	06/18/2025		A		413,839⁽²⁾	A	$0	2,437,089	D
Common Stock	06/20/2025		C⁽³⁾		104,761,535	A	$0	121,025,002	I	See Footnotes⁽⁴⁾⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series A Preferred Stock	$0	06/20/2025		C			389,416,484	⁽³⁾	⁽³⁾	Common Stock	97,354,127	⁽³⁾	0	I	See Footnotes⁽⁵⁾⁽⁶⁾
Series B Preferred Stock	$0	06/20/2025		C			29,629,630	⁽³⁾	⁽³⁾	Common Stock	7,407,408	⁽³⁾	0	I	See Footnotes⁽⁵⁾⁽⁶⁾

1. Name and Address of Reporting Person^*

HALBERT DAVID D

(Last)

(First)

(Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING

75039

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

1. Name and Address of Reporting Person^*

Caris Halbert, L.P.

(Last)

(First)

(Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING

75039

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Represents an award of restricted stock units that vest in accordance with the applicable grant agreement. These restricted stock units were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.

2. Represents an award of restricted stock units that vest in accordance with the applicable grant agreement.

3. Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock.

4. The Common Stock reported herein includes (i) 101,261,532 shares of Common Stock held of record by Caris Halbert, L.P, (ii) 8,528,805 shares of Common Stock held of record by ADAPT I Ltd., (iii) 8,414,427 shares of Common Stock held of record by Carisome I, L.P., (iv) 645,149 shares of Common Stock held of record by Caris Investment II Ltd, and (v) 2,175,089 shares of Common Stock held of record by Caris Investment III Ltd. Caris Investment Management, LLC is the general partner of each of Caris Halbert, L.P., Caris Investment II Ltd., and Caris Investment III Ltd. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively.

5. David D. Halbert is the managing member of Caris Investment Management, LLC and the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein.

6. The preferred stock reported herein includes (i) 3,500,003 shares of Common Stock underlying Series A Preferred Stock held of record by ADAPT I Ltd., (ii) 93,854,124 shares of Common Stock underlying Series A Preferred Stock held of record by Caris Halbert, L.P. and (iii) 7,407,408 shares of Common Stock underlying Series B Preferred Stock held of record by Caris Halbert, L.P.

Remarks:

Founder, Chairman, and Chief Executive Officer; ADAPT I Ltd. and Carisome I, L.P. are filing a separate Form 4 with respect to the transactions reported herein.

	David Halbert, /s/ J. Russel Denton, Attorney-in-Fact	06/23/2025
	Caris Halbert, L.P., /s/ J. Russel Denton, Attorney-in-Fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Caris Life Sciences (CAI) shares does David D. Halbert own after the reported transactions?

He beneficially owns about 121.0 million common shares (鈮�2.4 million direct, the rest indirect through affiliated entities).

What triggered the preferred-stock conversion disclosed in the Caris Life Sciences Form 4?

Each Series A and Series B share automatically converted into common stock at IPO closing on 20 June 2025 at a 0.25:1 ratio.

Were any shares sold by the insider in this filing?

No. All transactions were awards or automatic conversions; no dispositions or open-market sales occurred.

Does the Form 4 indicate additional dilution for CAI shareholders?

Yes. The conversion adds ~104.8 million new common shares, expanding the share base ahead of public trading.

Why was a 1-for-4 reverse stock split mentioned in the footnotes?

It adjusted all share counts effective 1 June 2025, ensuring reported numbers reflect the split-adjusted amounts for accuracy before the IPO.

AG真人官方

[Form 4] Caris Life Sciences, Inc. Insider Trading Activity

Insights

FAQ

How many Caris Life Sciences (CAI) shares does David D. Halbert own after the reported transactions?

What triggered the preferred-stock conversion disclosed in the Caris Life Sciences Form 4?

Were any shares sold by the insider in this filing?

Does the Form 4 indicate additional dilution for CAI shareholders?

Why was a 1-for-4 reverse stock split mentioned in the footnotes?

NASDAQ:CAI

CAI Rankings

CAI Latest News

CAI Latest SEC Filings

CAI Stock Data

AG真人官方

Trending News

[Form 4] Caris Life Sciences, Inc. Insider Trading Activity

Insights

Financial Analyst neutral

Corporate Governance Expert neutral

FAQ

How many Caris Life Sciences (CAI) shares does David D. Halbert own after the reported transactions?

What triggered the preferred-stock conversion disclosed in the Caris Life Sciences Form 4?

Were any shares sold by the insider in this filing?

Does the Form 4 indicate additional dilution for CAI shareholders?

Why was a 1-for-4 reverse stock split mentioned in the footnotes?

NASDAQ:CAI

CAI Rankings

CAI Latest News

CAI Latest SEC Filings

CAI Stock Data